Efficacy and Safety of HMM1-022 in Temporary Correction of Crow's Feet

Launched by HUMEDIX CO., LTD. · May 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called HMM1-022 to see how effective and safe it is for reducing crow's feet, which are the fine lines and wrinkles that appear around the eyes. The trial will compare HMM1-022 with another treatment known as Rejuran. Adults aged 19 and older who are willing to stop using other wrinkle treatments during the study can participate. However, there are some exclusions; for example, individuals with certain allergies, autoimmune diseases, or a history of serious health issues may not be eligible.

If you decide to join the trial, you will receive detailed information about the process and will need to give your written consent. During the trial, participants will be monitored to ensure their safety and to assess how well the treatments work. It’s essential to be aware that if you have had specific wrinkle treatments or surgeries recently, you may not qualify for the study. This trial aims to provide valuable insights into a new option for managing crow's feet and help improve treatment options for people looking to reduce these signs of aging.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Adult aged 19 years or older
• • Individuals who have voluntarily decided to participate in the clinical trial after receiving and understanding a detailed explanation, and who have provided written consent
• • Individuals who have agreed to discontinue all dermatological treatments, including wrinkle treatments around the eyes, during the clinical trial period
• • Exclusion criteria
• • 1. Individuals with a history of anaphylaxis or severe allergic diseases that may affect the clinical trial
• • 2. Individuals diagnosed with autoimmune diseases, sarcoid granulomatous pathology, or Osler\'s endocarditis
• • 3. Individuals with hypersensitivity to the investigational medical device, its components (polynucleotide sodium, hyaluronic acid sodium, lidocaine), or other amide-type local anesthetics
• • 4. Individuals with a history of bleeding disorders
• • 5. Individuals with a history of facial nerve paralysis or ptosis
• • 6. Individuals with significant facial asymmetry that may affect the clinical trial
• • 7. Individuals with skin diseases, infections, or abnormalities such as scars in the eye area that could affect the clinical trial
• • 8. Individuals with a history of keloid formation, hyperpigmentation, or hypertrophic scar in the evaluation area
• • 9. Individuals with a history of malignant tumors within 5 years prior to Visit 1 (screening), except those with treated basal cell or squamous cell skin cancer not in the eye area, or treated cervical cancer
• • 10. Individuals with clinically significant disorders or psychiatric conditions affecting the cardiovascular, gastrointestinal, respiratory, endocrine, immune, or central nervous systems, or those with conditions that may significantly impact the clinical trial
• 11. Individuals who have undergone or are scheduled to undergo treatments affecting the efficacy assessment of crow's feet wrinkles during the following periods:
• • Within 24 months before Visit 1 (screening) using Poly(L-Lactide) or Poly(ε-Caprolactone) for wrinkle treatment
• • Within 18 months before Visit 1 (screening) using Calcium hydroxylapatite (CaHA) for wrinkle treatment
• • Within 12 months before Visit 1 (screening) using hyaluronic acid for wrinkle treatment
• • Within 6 months before Visit 1 (screening) using collagen, botulinum toxin, or other wrinkle treatments
• • Within 6 months before Visit 1 (screening) undergoing invasive laser, deep dermabrasion, or other procedures or surgeries related to wrinkle treatment in the eye area
• • Insertion of permanent skin expansion implants like Softform or silicone in the eye area before screening
• • Starting or receiving a new oral or topical anti-wrinkle medication with wrinkle prevention effects within 3 months before Visit 1 (screening)
• 12. Individuals who have undergone the following drug therapies that could affect the evaluation of the investigational medical device:
• • Use of NSAIDs, antiplatelet agents, anticoagulants, immunosuppressants within 2 weeks before Visit 1 (screening), or required during the clinical trial period (excluding low-dose aspirin (100 mg, up to 300 mg/day))
• • Use of topical agents (steroids, retinoids: only medications, not cosmetics) in the eye area within 1 month before Visit 1 (screening) or planned use during the clinical trial
• • 13. Individuals who have received a COVID-19 vaccine within 3 weeks before the application of the investigational medical device or are planned to receive it within 4 weeks after application
• • 14. Individuals with ongoing infectious diseases, including COVID-19, or suspected COVID-19 infection within 2 weeks before screening
• • 15. Individuals who have been administered or undergone other investigational drugs or devices within 1 month before Visit 1 (screening), or within 6 months for studies related to crow's feet wrinkles
• • 16. Individuals with positive results for viral tests (HBs Ag, HCV Ab, HIV Ab) performed at Visit 1 (screening) or within 1 month before screening
• • 17. Individuals with a history of alcohol or drug addiction
• • 18. Pregnant or breastfeeding women
• • 19. Individuals planning to become pregnant during the clinical trial or those who, along with their partners (or spouses), do not agree to use medically acceptable contraception methods (examples include: hormonal contraceptives, proven failure rates intrauterine devices (IUDs), double barrier methods, sterilization)
• • 20. Individuals deemed unsuitable for participation in the clinical trial based on the investigator\'s judgment

Trial Officials